Abstract

Glycoprotein VI (GPVI) has a crucial role in platelet responses to collagen. Still, little is known about its interaction with its ligands. In binding assays using soluble or cell-expressed human GPVI, we observed that (i) collagen, and the GPVI-specific ligands collagen-related peptides (CRP) and convulxin, competed with one another for the binding to GPVI and (ii) monoclonal antibodies directed against the extracellular part of the human receptor displayed selective inhibitory properties on GPVI interaction with its ligands. Monoclonal antibody 9E18 strongly reduced the binding of GPVI to collagen/CRP, 3F8 inhibited its interaction with convulxin, whereas 9O12 prevented all three interactions. These observations suggest that ligand-binding sites are distinct, exhibiting specific features but at the same time also sharing some common residues participating in the recognition of these ligands. The epitope of 9O12 was mapped by phage display, along with molecular modeling of human GPVI, which allowed the identification of residues within GPVI potentially involved in ligand recognition. Site-directed mutagenesis revealed that valine 34 and leucine 36 are critical for GPVI interaction with collagen and CRP. The loop might thus be part of a collagen/CRP-binding site.

Highlights

  • Glycoprotein VI (GPVI) has a crucial role in platelet responses to collagen

  • Competition between Collagen, collagen-related peptides (CRP), and Convulxin for the Binding to Cell-expressed GPVI—The hematopoietic cell line HEL was engineered to overexpress recombinant human GPVI [3]. rGPVI associated with FcR␥

  • RGPVI-HEL cells were able to adhere to immobilized collagen, CRP, and convulxin in a timeand dose-dependent manner [17]. rGPVI-HEL expressed a low level of integrin ␣2␤1 at their surface as indicated by flow cytometry using a fluorescein isothiocyanate-coupled antiCD49b

Read more

Summary

EVIDENCE FOR THE EXISTENCE OF DISTINCT BINDING SITES*

In binding assays using soluble or cell-expressed human GPVI, we observed that (i) collagen, and the GPVI-specific ligands collagen-related peptides (CRP) and convulxin, competed with one another for the binding to GPVI and (ii) monoclonal antibodies directed against the extracellular part of the human receptor displayed selective inhibitory properties on GPVI interaction with its ligands. Monoclonal antibody 9E18 strongly reduced the binding of GPVI to collagen/CRP, 3F8 inhibited its interaction with convulxin, whereas 9O12 prevented all three interactions These observations suggest that ligand-binding sites are distinct, exhibiting specific features but at the same time sharing some common residues participating in the recognition of these ligands. To locate ligand-binding site(s) on human GPVI, we have produced a panel of monoclonal antibodies (mAbs) directed against the extracellular part of human GPVI Their ability to prevent GPVI interactions with collagen, CRP, and convulxin was measured in a binding assay using purified proteins and in a cell adhesion assay. Pates in the binding to collagen, with, in particular, Val-34 and, to a lesser extent, Leu-36 being critically involved in the interaction

EXPERIMENTAL PROCEDURES
Wild Type and Mutant Recombinant Soluble Human GPVI
ELISA and Binding Assays Using Purified Proteins
Cell Adhesion Assay and Preparation of Human Platelets
Homology Modeling of GPVI
RESULTS
SCGLGVVCGAALVA GQELLACGLFSVCLS GQRSSVGGCGLHLVC KNGVFLCGLGLVCPD
DISCUSSION
Statistical significance
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call